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ABSTRACT 
 
 Since its emergence in the early 1980’s HIV has killed approximately 32 million people, 
and continues to kill over half a million people every year. Significant research into potential 
vaccines and cures for HIV has been ongoing for decades but has been largely unsuccessful. One 
of the more promising technologies that is being investigated to develop an HIV vaccine is 
recombinant vaccine technology. The study presented in this thesis aims to use simian varicella 
virus (SVV) and simian immunodeficiency virus (SIV) to act as a model for recombinant vaccine 
development. If a recombinant SVV-SIV vaccine can be proven safe and effective at preventing 
SIV in monkeys, it could provide data to aid in the development of a potential HIV vaccine for 
humans. Specifically, it could aid in the development of a recombinant varicella zoster virus 
expressing human immunodeficiency virus antigens (rVZV-HIV).  
 In this thesis, sera from rhesus macaques that were immunized with a rSVV-SIV vaccine 
are analyzed. Antibody titers against SVV were determined using an indirect ELISA assay.  The 
goal of this thesis is to evaluate the humoral response against the SVV vector in rSVV-SIV 
immunized rhesus macaques.  
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Chapter 1: Background on HIV/AIDS 
Emergence 
 In the early 1980’s doctors in the United States started to notice a peculiar rise in rare 
cancers and opportunistic infections among young, homosexual men. The cause of these 
infections was unknown, but patients had very low levels of CD-4 lymphocytes and once they 
were symptomatic, death was almost certain. Scientists found that serum from HTLV-1, a known 
retrovirus that attacked CD-4 lymphocytes, infected patients weakly stained cells from AIDS 
patients, and suspected that the cause of AIDS could be another retrovirus. This theory would 
prove to be true in 1983 when scientists at the Pasteur Institute isolated retroviral particles from 
sera of AIDS patients.  This virus, which would later prove to the be the cause of AIDS, became 
known as the human immunodeficiency virus (Greene, 2007).  
  Simian immunodeficiency virus, SIV, is HIV’s closest relative and is endemic to many of 
Africa’s native primate populations. It is believed that there have been many cross-species 
transmission events of SIV viruses to humans. Most of these transmissions resulted in viruses 
with limited transmissibility, but one in particular, HIV-1 group M, has become the main cause 
of the AIDS epidemic (Sharp & Hahn, 2011). In 1986, three years after HIV was first isolated, a 
second morphologically similar but antigenically distinct virus was discovered in humans. This 
second virus was named HIV-2 and is believed to have arisen from a separate cross-species 
interaction with a sooty mangabey monkey somewhere in Guinea-Bissau (Lemey et al., 2003). 
Concerns that further cross-species interactions could lead to new and more dangerous HIV 
viruses are valid and motivate continued research into how such interactions can be limited.   
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Transmission 
 HIV is transmitted through bodily fluids such as blood, semen, and breast milk. Common 
routes of transmission are sexual contact across mucosal surfaces, mother-infant exposure, and 
percutaneous inoculation (Shaw, 2012). Contaminated blood products can also transmit HIV, 
although rigorous protocols and testing have made this route of transmission rare in developed 
nations. HIV infections across mucosal membranes are aided by micro abrasions or other defects 
and can infect Langerhans cells, dendritic cells, or CD4 lymphocytes at the point of infection 
(Shaw, 2012).  
 HIV mutates very quickly and as a result, when someone is exposed to HIV they are 
often exposed to many genetic variants. There are many cofactors that can affect the 
transmissibility of HIV. Studies have shown increased transmissibility in people who have STI’s, 
are uncircumcised, or are engaged in particularly risky sexual behavior (Powers, 2008). If an 
individual is known to be HIV positive and has a long-time partner who is HIV negative, 
measures can be taken to lower the risk of transmission to the partner. Antiretroviral therapy can 
be taken by the HIV+ individual to lower viral load, condoms can be used to control exposure, 
and the HIV negative partner can take pre-exposure prophylaxis medication. When combined 
these methods have been found very effective at controlling HIV transmission (Haberer et al., 
2015). 
 
HIV Structure and Replication 
 HIV is an enveloped, diploid, single-stranded positive-sense RNA virus. Mature virions 
are roughly spherical in shape with trimers of the gp120 glycoprotein embedded in the envelope. 
Gp120 glycoproteins are anchored to the membrane by the gp41 protein. Inside of the envelope 
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is a bullet shaped capsid formed from repeating units of the p24 protein. The capsid protects the 
two copies of the viral genome. Also contained in each virion is a reverse transcriptase which the 
virus uses to convert its vRNA into DNA that can then be integrated into the host cell genome to 
establish the proviral phase.  
 
 
Figure 1: HIV viral structure and viral entry via gp120 interactions with cellular 
CD4 receptors (Sanders, 2012). 
 
 HIV entry into the host cell is dependent on gp120 glycoproteins interactions with host 
cell CD4 receptors. These CD4 receptors are present on many cells in the immune system, but 
are most prevalent on CD4+ T lymphocytes. Binding of the gp120 glycoprotein trimer to three 
cellular CD4 receptors induces a conformational change in the gp120 glycoproteins that enable 
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interactions with coreceptors. These coreceptors induce conformational changes in the gp41 
protein and subsequent fusion of the viral envelope with the host cell membrane (Claeys & 
Vermeire, 2019). After the fusion of the membranes, the capsid is released into the cytoplasm 
and the reverse transcriptase begins to transcribe the vRNA into DNA that is then inserted into 
the host genome. Once this is complete the vRNA is degraded and the virus replicates using the 
host cell’s machinery.  
  
Disease Progression 
 After exposure it usually takes a few weeks before the onset of symptoms. In the first 
stage of infection, known as the acute infection period, levels of CD4+ T cells drop and viral 
load increases sharply. This stage of infection is often associated with fever, chills, rash, fatigue, 
and general malaise. The symptoms from the acute stage of HIV are difficult to distinguish from 
other illnesses such as the flu or common cold. The length of time of the acute stage varies, but is 
generally between 2-10 weeks (Hernandez-Vargas et al., 2013). After the acute stage of 
infection, CD4+ T cell counts recover to near-normal levels and viral load decreases 
dramatically. During this latent period infected individuals are asymptomatic, although HIV 
continues to replicate and infect new cells. Because people often do not know when they are 
exposed to HIV and the symptoms are easily explained by other illnesses, it is common for 
individuals in the latent stage to not know they are infected. This is particularly worrisome 
because although they are not symptomatic, individuals in the latent stage can still spread HIV. 
The latent stage usually lasts 7-10 years, but can vary significantly between individuals. 
Following the latent stage, viral loads rise rapidly while CD4+ T cell counts drop. Once CD4+ T 
cells drop below 200cells/mm3 the individual is said to have acquired immunodeficiency 
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syndrome, also known as AIDS. AIDS is characterized by an increase in opportunistic infections 
by pathogens that a healthy individual would usually defeat. Because of their weakened immune 
system, illnesses like the flu or common cold can quickly turn deadly. It is also common for 
AIDS patients to develop rare malignancies such as Kaposi’s Sarcoma. Ultimately AIDS kills 
individuals not because of the underlying HIV infection, but the compounding illnesses 
associated with an insufficient immune system.  
 
Diagnosis 
When transmitted through mucosal tissues, HIV typically takes 7-21 days before it is 
detectable in the blood. This eclipse period results from the amount of time it takes for a 
sufficient number of viral particles to replicate and enter the bloodstream before they reach 
detectable levels. The most common way to test for HIV infections is through rapid antibody 
detection. Rapid antibody tests can give results in as little as 30 minutes, making them 
convenient for clinical use. Rapid HIV tests are treated as a screening test, not a final diagnosis, 
because false positives are possible, though rare. If an individual test positive on a rapid test this 
is called a “preliminary positive” which can then be confirmed by either Western Blot or 
immunofluorescent assays (Greenwald et al., 2006). If an individual tests positive on a rapid test 
but negative on a confirmatory test, follow up testing is advised at around 4 weeks.  
 
Treatment 
When HIV first emerged in the 1980’s there were no cures, vaccines, or therapies to help 
treat AIDS patients. Four decades later and with countless hours and billions of dollars poured 
into research, there is still no cure or vaccine, but effective therapies to help people live longer 
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lives with HIV have been developed. The current standard for HIV treatment is high activity 
antiretroviral therapy (HAART). HAART works by combining antiretroviral drugs of different 
classes to make it very difficult for the virus to replicate and infect new cells (Gange et al., 
2002). Early attempts to treat HIV focused on similar methods, but instead of using multiple 
antiretroviral drugs, patients were only given one. This approach works for the most viral 
infections, but it was not effective at treating HIV. HIV has a very high mutation rate and given 
enough time was often able to develop resistance to a single drug. HAART solves this problem 
because the multiple methods of inhibition make it much more difficult for the virus to mutate 
around. The downside to HAART is that it does not cure the underlying HIV infection and must 
be taken for the rest of one’s life. HAART does a great job of lowering viral loads in the blood, 
but it cannot kill cells that are latently infected. While HAART has proven very effective there is 
still a need for other treatments and for a vaccine to fully eliminate HIV. Further research into 
these areas is promising with head of the United States National Institute of Allergy and 
Infectious Diseases Anthony Fauci saying, “With collective and resolute action now and a 
steadfast commitment for years to come, an AIDS-free generation is indeed within reach” (Fauci, 
2012). 
The persistence of HIV in its proviral stage is one of the biggest barriers to creating 
effective cures. The size and scope of these viral reservoirs is not fully understood, but research 
from John’s Hopkins suggest that HIV infected cells can replicate without releasing infectious 
virus and then release virus upon subsequent stimulation (Hosmane et al., 2017). 
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CHAPTER 2: BACKGROUND ON VACCINES  
 
HIV Vaccines 
 Vaccine studies cannot be done on humans until they have first been tested in animal 
models. Some common animal models are mouse, feline, rabbit, pig, and non-human primate 
(Kiros et al., 2012). For this project non-human primate models were used to test the efficacy of 
an experimental vaccine. The ultimate goal of this project is to develop a recombinant varicella-
zoster virus vaccine (rVZV) that can induce immunity to multiple HIV proteins. The simian 
model is ideal for this project because non-human primates are susceptible to simian varicella 
virus (SVV) and simian immunodeficiency virus (SIV) which are closely related to varicella-
zoster virus (VZV) and human immunodeficiency virus (HIV) respectively. The immediate goal 
then is to create a recombinant simian varicella virus vaccine that can also induce immunity to 
simian immunodeficiency virus (SIV). To understand the advantages of the simian model, a 
discussion of the similarities between VZV and SVV, as well as HIV and SIV is included below.   
 As discussed earlier in this paper, HIV originated from cross species interactions with 
primates infected with SIV. It follows then that the viruses are very similar in their structure, 
function, and mode of infection. Both SIV and HIV are retroviruses with RNA genomes that 
infect the host and cause latent infections. After the latent period, both viruses destroy the host 
immune system and ultimately lead to death. Both viruses attack CD4+ cells of the immune 
system and both viruses have similar pathophysiology which include a decline in the number of 
CD4+ T cells, neurologic abnormalities, and opportunistic infections (Fauci, 1997).  
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 SVV and VZV are also very closely related. They share 75% DNA homology, are both 
alpha-herpesviruses, and share immunological cross reactivity (Nicholas, 2011). Both viruses 
produce varicella, an acute and highly contagious disease characterized by small, itchy blisters; 
fever; and malaise. SVV and VZV can both sit latent in ganglionic neurons and become 
reactivated by environmental stressors to produce zoster. In humans, acute illness associated with 
VZV infection is referred to as chickenpox. While VZV was once very common, the introduction 
of the VZV Oka vaccine in 1995 has led to a dramatic drop in chickenpox and has proven to be a 
safe and effective vaccine. Because the VZV vaccine is a live attenuated vaccine, it presents the 
opportunity for researchers to add foreign genetic material into the VZV genome. There are 
many advantages to using VZV vectors to introduce foreign antigens. VZV has a large genome 
with dispensable regions which allow the introduction of multiple foreign genes, VZV is known 
to be able to induce a strong immune response, and the VZV Oka vaccine has proven to be safe 
and effective. For these reasons, there has been significant research into recombinant vaccines 
using VZV Oka as a vector for the expression of foreign antigens.   
The study presented in this thesis is based on over a decade of research into recombinant 
SVV viruses. Two previous studies have tested the hypothesis that recombinant SVV-SIV 
vaccines can be used to induce immune responses against SIV (Traina-Dorge et al., 2010; Ou et 
al., 2007). Both studies have found that rSVV-SIV vaccines can induce low levels of neutralizing 
antibodies to SIV in immunized primates. One of the studies also demonstrated that it can reduce 
viral loads following intravenous challenge with pathogenic SIV (Traina-Dorge et al., 2010).  
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Recombinant Vaccines 
 Some of the most successful vaccines that have been developed are live attenuated 
vaccines with examples including measles, rubella, and varicella vaccines (Principles of 
Vaccination). Live attenuated vaccines produce a very robust immune response and usually only 
have to be taken once.  While live attenuated vaccines are very effective at inducing the desired 
immune response, they also come with risks. In order for live attenuated vaccines to work they 
have to replicate in the host. Because the virus is weakened, the vast majority of people who are 
immunized will never become symptomatic, but it is possible for some individuals to develop 
full blown infections. People with compromised immune systems are at the greatest risk for 
developing these infections. For viruses like VZV that are not particularly deadly to children at 
the age of vaccination, live attenuated viruses are a justified risk. For viruses that are very deadly 
like HIV, live attenuated vaccines carry an unjustifiable risk. Fortunately, advancements in 
biochemistry have now enabled researchers to pursue recombinant genomic and recombinant 
protein vaccines that avoid the risk of attenuating deadly viruses.  
 There are many types of recombinant vaccines, but the ones studied in this thesis are 
created by the insertion of a viral gene (SIV env and gag) that codes for a specific antigen into 
the genome of another virus (SVV). These vaccines work by inducing the host to generate the 
foreign antigens coded for in the viral genome without producing infectious virions. Because no 
pathogenic virions are produced, these vaccines are much safer than live attenuated vaccines.  
Using viral vectors to introduce foreign genetic material has unique advantages when 
compared to other recombinant vectors. Because viral vectors infect cells, they induce the 
production of foreign antigens within the host cell. By generating the viral antigens 
intracellularly, antigens can be processed and loaded onto major histocompatibility complex 
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class I molecules on the surface of infected cells, and help facilitate cellular immune responses 
(Nascimento & Leite, 2012). The production of both cellular and humoral immunity is important 
in the development of vaccines against resilient pathogens such as HIV. Because viral vectors 
can induce both types of immunity they are the focus of extensive research regarding HIV 
vaccines. One of the most successful HIV vaccine candidates to date was a recombinant 
adenovirus expressing three different HIV surface antigens. This vaccine made it to human trials, 
however in these trials it was found that the vaccine was not sufficiently protective against HIV 
and that it increased the rate of HIV infection in vaccinees that had pre-existing immunity to the 
adenovirus vector (Buchbinder et al., 2008).  
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CHAPTER 3: METHODS 
 
Experimental Design 
  The vaccine used to immunize primates that are analyzed in this thesis is a recombinant 
SVV virus expressing the SIV env and gag antigens. The rSVV-SIV virus was created using the 
SVV cosmid recombination system (Gray & Mahalingam, 2005). The presence of SIV env and 
gag genes in the rSVV-SIV genome was confirmed using PCR. Rhesus macaques from the 
Tulane National Primate Research Center were used as the test subjects for this project. The 
experimental group was inoculated with the rSVV-SIV env and gag vaccines at 0, 8, 24, 43, and 
54 weeks while also receiving SIV gag/env protein vaccines at 24, 43, and 54 weeks. The 
subjects were challenged with SIVmac251, a pathogenic macaque strain of SIV, intrarectally 
beginning at week 61. This method of challenge was chosen to best replicate real-world 
transmission of HIV. Intravenous challenge, while an option, is a much less common route of 
transmission so it was not chosen for this study. Sera was collected at regular intervals over the 
course of the trial to analyze the immune response. Pre-inoculation sera was also collected to 
ensure that none of the monkeys had previously been infected with SIV or SVV.  
 A heterologous prime boost method was chosen for the immunization protocol in this 
study. Prime boosted immunization protocols are a common method used to increase the desired 
immune response by using multiple inoculations of a vaccine. Because both a recombinant 
vaccine and purified protein vaccines were used in the immunization protocol it is said to be 
heterologous. The immunization protocol can be seen in the figure below.  
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Figure 2. Immunization Protocol 
 
Indirect ELISA 
 ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed 
for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and 
hormones (Overview of ELISA). ELISA assays work by using enzyme linked antibodies to bind 
to the target antigen and then adding a substrate that the bound enzyme can interact with to 
produce a colored product. The ELISA assays performed for this thesis were indirect ELISA 
assays. In indirect ELISA there are two antibodies: a primary antibody and a conjugated 
secondary antibody. The primary antibody binds specifically to the target antigen. For this 
project the primary antibody was the SVV antibodies found in the monkey’s sera. The secondary 
antibody is an antibody that binds to the constant region of the primary antibody and is 
conjugated with an enzyme. For this project the secondary antibody was mouse anti-monkey 
IgG-HRP (horseradish peroxidase). After sequential incubation with the primary antibody 
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followed by the secondary antibody, a substrate is added that the enzyme on the secondary 
antibody can react with to produce a colored product.  
 
Figure 3. Indirect ELISA. Immobilized antigen is bound to the sides of the well. 
Primary antibody binds to the target antigen while unbound antibody is washed off. 
Secondary antibody is added and binds to the constant region of the primary antibody 
while unbound secondary antibody is washed off. Substrate is added, converted into 
colored product by conjugated enzyme, and the signal is then analyzed (ELISA Assays).  
 
Protocol 
SVV infected vero cells were grown in a 175cm confluent flask. The infected cells were 
scraped from the sides of the flask using a sterile scraper, spun for 10 minutes at 1500xg, and the 
resulting pellet was suspended in 10mL of 1x PBS. The cells were then spun again for 10 
minutes at 1500xg and the resulting pellet was suspended in 2mL of 1% triton-X, 0.1M Glycine-
NaOH buffer. The cells were then incubated on ice for 30 minutes and sonicated in a 2mL 
centrifuge tube. The solution was transferred to a round bottom centrifuge tube and spun down at 
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41,000xg. This lysate, containing SVV antigens, was then aliquoted and stored at -80°C to be 
used during all ELISA assays. To prepare a 96 well plate, a tube of SVV antigen was brought to 
room temperature, diluted to a concentration of 5 µg/mL using PBS, and 100µl of the 5 µg/mL 
solution was added to each well. This completed the plate preparation.  
 The day before analyzing sera, the appropriate number of wells on the 96 well plate was 
prepared by removing the 100µl of lysate and washing two times with 100µl of phosphate 
buffered saline with tween (PBS-T). Next 100µl of blocking buffer was added to each well. The 
blocking buffer was made by dissolving 3g of Bovine Serum Albumin and 0.2g Sodium Azide in 
100mL of 1xPBS. The blocking solution functions to block non-specific binding of the primary 
antibody by adding a generic protein (BSA) to occupy non-specific binding sites. The plate with 
blocking buffer was then stored overnight at 4°C.  After incubating overnight, the blocking 
buffer was removed and each well was washed two times with 100µl PBS-T. The plate and all 
reagents were allowed to come to room temperature while serial dilutions of the appropriate 
monkey sera were prepared. Once the dilutions were prepared and the reagents were at room 
temperature, 100µl of each dilution was loaded onto the plate. Dilutions were loaded from most 
dilute to least dilute and allowed to incubate for one hour. After incubation, each well was 
emptied and washed three times with 200µl PBS-T. Next, a 1:2000 dilution of the secondary 
antibody, mouse anti-monkey IgG HRP-conjugated, was prepared and 100µl was loaded into 
each well. The secondary antibody was incubated on the plate for 30 minutes. After incubation, 
the secondary antibody was removed and each well was again washed three times with 200µl 
PBS-T. Next, 100µl of tetramethylbenzidine, a substrate that the HRP enzyme converts to a blue 
product, was loaded into each well and incubated for exactly 20 minutes. At 20 minutes 100µl of 
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acid stop solution, a solution that terminated the TMB-HRP reaction by lowering the pH, was 
quickly loaded into each well and the plate was analyzed by the plate reader in Shoemaker 209.  
Previous studies using positive and negative controls determined that a cutoff value of 0.1 
absorbance at 450nm was appropriate for this assay. If absorbance was above 0.1 for a well, the 
well was said to be positive; if absorbance was below 0.1 the well was said to be negative. Serial 
dilutions of each sera were analyzed with the goal of finding the dilution at which the sera 
became negative. The antibody titer was recorded as the reciprocal of the value of the dilution 
before the sera became negative.  
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CHAPTER 4: SVV ANTIBODY RESPONSE 
 
Results 
 Sera from each monkey was collected at seven different times: pre-inoculation, 4 weeks 
after vaccination one (PV1), 2 weeks after vaccination two (PV2), 2 weeks after vaccination 
three (PV3), 2 weeks after vaccination four (PV4), at vaccination five (PV5), and 4 weeks after 
testing SIV+. These sera were all run through ELISA assays to measure SVV antibody titers 
according to the protocol discussed above. The results for three different monkeys LK56, LK58, 
and LK60 are shown in the figures below.  
 
 Figure 4. LK60 Pre-Immune & PV1 Absorbance 
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 LK56 LK58 LK60 
Pre-inoculation 250 1000 250 
PV1 4000 8000 16000 
PV2 32000 32000 32000 
PV3 32000 32000 32000 
PV4 32000 32000 32000 
PV5 32000 32000 32000 
SIV+ 4week 32000 32000 32000 
 
 Table 1. SVV Antibody Titers for LK56, LK58, and LK60 
 
 Figure 5. SVV Antibody Titers as a Function of Time.  
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 Figure 4 shows the absorbance values for LK60 pre-immune and PV1 sera. This figure 
illustrates the method by which absorbance values from indirect ELISA assays were converted 
into antibody titers. The antibody titer was recorded as the reciprocal of the greatest dilution that 
is above the cutoff value. The pre-immune sera crossed the cutoff value at the 1-500 dilution, so 
the antibody titer was recorded as the reciprocal of the previous 1-250 dilution. The PV1 sera 
crossed the cutoff value at 1-32k so the antibody titer was recorded as the reciprocal of the 
previous 1-16k dilution. The data in Table 1 and Figure 5 was calculated by repeating this 
process for the absorbance values from each assay.  
 The results from Table 1 and Figure 5 show that in all three animals there was a 
significant antibody response after the 1st immunization. LK56 saw a 16-fold increase, LK58 saw 
an 8-fold increase, and LK 60 saw a 64-fold increase in SVV antibody titer from pre-inoculation 
to PV1. After the second vaccination there was another significant increase in SVV antibody 
titers. The combination of the rSVV-SIV vaccines and purified SIVenv and SIVgag protein 
vaccines given as the third, fourth, and fifth vaccinations were successful in maintaining high 
antibody titers throughout the duration of the study.  
 
Discussion  
 The data presented in this thesis shows that there was a strong humoral response to the 
SVV vector used in the rSVV-SIV vaccines. The monkeys from this study were never 
challenged with pathogenic strains of SVV, but the high antibody titers against the SVV vector 
suggest that the vaccine may be effective at protecting against future SVV infections. Although 
the primary goal of these recombinant vaccines is to immunize against SIV not SVV, a thorough 
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analysis of the immune response to both the vector and the recombinant SIV genes is important 
for future research. 
 While it was not the focus of this thesis, data on the immune response to SIV in the 
immunized monkeys was also collected in this study. The data showed that the immunization 
protocol using rSVV-SIV gag/env vaccines with a purified SIV gag/env protein booster was 
effective in eliciting a strong antibody and cellular immune response to SIV. After being 
challenged multiple times with a pathogenic strain of SIV, 37% of immunized monkeys never 
contracted SIV. The 63% of primates that did contract SIV exhibited lower viral loads when 
compared to controls. These promising results demonstrate the efficacy of the simian model and 
can be used to help guide other studies into recombinant vaccines.   
To date all research done using these rSVV-SIV gag/env vaccines has been performed on 
monkeys that were naïve to SVV. Future studies could evaluate the immune response to rSVV-
SIV vaccines in monkeys that had been previously infected with SVV. These studies could 
analyze how pre-existing SVV antibodies affect the rSVV-SIV vaccine and its ability to illicit an 
immune response. Other future research could focus on the simian model using rSVV-SIV 
vaccines, but using different SIV proteins.  
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